A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1(+) soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival

Chawla, S. P., Van Tine, B. A., Pollack, S., Ganjoo, K. N., Elias, A. D., Riedel, R. F., Attia, S., Choy, E., Okuno, S. H., Agulnik, M., von Mehren, M., Livingston, M. B., Keedy, V. L., Verschraegen, C. F., Philip, T., Bohac, G. C., Yurasov, S., Lu, H. L., Chen, M., Maki, R. G. (May 2019) A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1(+) soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival. In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO).

URL: https://ascopubs.org/toc/jco/37/15
Item Type: Conference or Workshop Item (Poster)
Subjects: diseases & disorders > cancer > drugs and therapies > chemotherapy
diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matthew Dunn
Date: May 2019
Date Deposited: 18 Oct 2019 18:55
Last Modified: 18 Oct 2019 19:09
URI: https://repository.cshl.edu/id/eprint/38615

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving